Atropine 0.01% Eyedrops for Evolutive Myopia Treatment in Children
Recruiting
Observational Study
Myopia
Children
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- Up to 18
- Sex
- Any
- Study type
- Observational
- Participants needed
- 50 (estimated)
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Prevalence of myopia and its complications has been increasing over the past decades, especially among children and adolescents. It reaches record levels in Asia: nearly 80% of the population in some regions in 2012 where the investigators speak in terms of epidemic.
ATROPINE 0.01% eyedrops one drop per day is today an evolutive myopia treatment, whose results are promising.
The investigators us…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Children with active myopia treated with ATROPINE 0.01% eye drops
* patient affiliated with a social security organization
* agreement of both parents
Exclusion Criteria:
* non compliance with treatment
Contacts